Scalper1 News
Illumina (ILMN), a maker of DNA sequencing products, said Thursday that it has struck strategic partnerships with several big drugmakers to develop what it calls a universal next-generation sequencing-based oncology test system for cancer diagnosis. The initial strategic partners include AstraZeneca (AZN), Janssen Biotech and Sanofi (SNY). Illumina says the system will be used to conduct clinical trials for specific cancer therapies. It will help Scalper1 News
Scalper1 News